Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01828294 · ClinicalTrials.gov registry record · Phase 1
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
A Phase 1 study, sponsored by St. Louis University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01828294 is a Phase 1 study that was terminated before completion, run by St. Louis University. The registered enrollment target is 4 participants.
The verdict
NCT01828294, a Phase 1 study, was terminated before completion, sponsored by St. Louis University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients may or may not be receiving anticholinesterase agents. A common treatment for patients with this disease includes the administration of intravenous immunoglobulin (IVIG), which is a plasma protein that is given to help maintain adequate antibody levels to prevent infections and decrease the symptoms of the disease of Myasthenia Gravis. This study is being done to test if giving this medication in a subcutaneous form (into the fat of the abdomen, legs and thighs) will be better tolerated for patients with Myasthenia Gravis.
Interventions
- DRUG Subcutaneous immunoglobulins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-10 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01828294
The ClinicalTrials.gov registry entry for NCT01828294 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Louis University, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Subcutaneous immunoglobulins is the first listed.
NCT01828294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01828294 about?
NCT01828294 is a clinical study titled "Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis". The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients may or may not be receiving anticholinesterase agents. A common treatment for patients with this disease includes th...
What is the current status of trial NCT01828294?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2011-10. Estimated completion is 2017-12.
What interventions are being tested in trial NCT01828294?
The interventions under investigation include: Subcutaneous immunoglobulins (DRUG).
Who is sponsoring clinical trial NCT01828294?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.